– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study –  – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 –  AUSTIN, TX & DURHAM, NC, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company ...

As expectations of the future tamper down, Novo Nordisk ( NVO ) is currently adequately priced in the near term, but likely underpriced compared to its mid- to long-term potential. At a 25% revenue CAGR over the next five years, theI am an individual investor and student of value investing. I specialize in strategic analysis of situations, trying to assess stocks with common sense and simple valuation models to add robustness to my thinking. I am sector agnostic and my primary focus in stock picking is on m ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (LLY 0.92%) announced its full results and reiterated its earlier 2025 forecast. The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control.The stock has bounced back since lowering its 2024 guidance in mid-January and is now up more than 10% year to date.Let's take a closer look at the comp ...

                World’s First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules  Kelowna, British Columbia – February 6, 2024 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide (“FTS”) rodent biodistribution study (the “Study”). Distribution of a drug once it enters the body can provide vital clues as to the understandi ...

Helixberg is an independent biotech publication providing concise and insightful briefings on major biotech catalysts and portfolio strategies. We are a team of healthcare professionals who launched this community following long careers in the biotech sector and hedge fund industry. With billions of dollars invested in groundbreaking pharmaceutical research, the biotech industry is moving at lightning speed. Over our careers we were in awe how little some experts in the traditional media understand to be pr ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Happy Tuesday! Most people quit a highly popular class of weight loss and diabetes drugs called GLP-1s within a year of starting them, several studies have shown. But new research has more details on who is more likely to stay on the pricey drugs, which cost roughly $1,000 per month before insurance and other rebates. Many i ...

Wall Street has high hopes for development-stage pharmaceutical company Viking Therapeutics.Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some of the most popular ones on the market today, including Ozempic, Wegovy, Mounjaro, and Zepbound. Each of these GLP-1 treatments are developed by either Novo Nordisk or Eli Lilly.Although Novo Nordisk and Eli Lilly are the m ...

Company Overview - Global Partners LP (GLP) shares increased by 6.8% to close at $56.69, with a notable volume of shares traded, reflecting strong investor interest [1] - The stock has gained 14.1% over the past four weeks, indicating a positive trend [1] Strategic Developments - The recent surge in units is attributed to the company's expansion into electric vehicle (EV) charging infrastructure, adding six new EV chargers in New Hampshire [2] - This initiative is supported by nearly $0.5 million in funding from the New Hampshire Volkswagen Environmental Mitigation Trust DCFC Infrastructure program, highlighting a significant growth strategy [2] Dividend Information - The board of directors declared a quarterly cash dividend of 74 cents per unit, representing a 1.4% sequential increase, to be paid on February 14, 2025 [2] - This combination of expansion efforts and a growing dividend likely contributed to investor optimism [2] Earnings Expectations - The company is expected to report quarterly earnings of $0.24 per share, reflecting a year-over-year decline of 83% [3] - Revenues are projected to be $5.8 billion, marking a 31.6% increase from the same quarter last year [3] Stock Performance Insights - The consensus EPS estimate for Global Partners has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, indicating the importance of monitoring future earnings updates [4] Industry Context - Global Partners operates within the Zacks Oil and Gas - Refining and Marketing - Master Limited Partnerships industry, where Targa Resources, Inc. (TRGP) also operates [4] - Targa Resources has seen a 1.2% increase in its stock price, with a 13.7% return over the past month, reflecting positive industry trends [4][5]

Dr. Reddy's Laboratories Limited (NYSE: RDY ) is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased revenue from new products within the high-growth segments like biosimilars and GLP-1. I believeI am a value focused investor, conducting fundamental research on sectors like but not limited to chemicals, homebuilders, building materials, industrials and metals & mining. I prefer to invest in stocks which are cheaply available and have a catalyst in the nea ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.For the last couple of years, the pharmaceutical sector has become infatuated with glucagon-like peptide 1 (GLP-1) agonists used to treat diabetes and help with chronic weight management. While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (LLY 2.45%) has two blockbuster weight loss drugs of its ...